Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial pneumonia characterized
by a poor response to therapy and a dismal prognosis. Historically, the fibrotic process in IPF …

Idiopathic pulmonary fibrosis (IPF) is a rare, progressive disease of the lungs with unknown
aetiology. Currently, there is no therapy that is specifically approved to be used for IPF …

Idiopathic pulmonary fibrosis (IPF) is an under-recognised, rare, progressive disease of the
lungs with unknown aetiology and high mortality. The currently advocated pathogenic …

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with a prognosis
that can be worse than for many cancers. The initial stages of the condition were thought to …

Idiopathic pulmonary fibrosis (IPF) is a progressively fibrotic disease with a median survival
of 3-5 years. Despite recent advances the pathophysiology of the disease remains not fully …

Idiopathic pulmonary fibrosis (IPF) is a progressive and invariably fatal disease with a
median survival of less than three years from diagnosis. The last decade has seen an …

Pirfenidone is the first antifibrotic agent to be approved for the treatment of pulmonary
fibrosis. Idiopathic pulmonary fibrosis (IPF) is one of the idiopathic interstitial pneumonias …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial pneumonia
of unknown cause, occurring in adults and limited to the lungs. In the past, treatment was …

Idiopathic pulmonary fibrosis (IPF) is the most common and lethal form of idiopathic
interstitial pneumonia. The disease, which occurs primarily in middle-aged and older adults …

Introduction: While many pharmacologic therapies for the treatment of idiopathic pulmonary
fibrosis (IPF) have been evaluated via randomized, placebo-controlled clinical trials (RCTs) …